Study testing treatment options for children and adults with RMS
Treatments studied
Part of Cancer clinical trials.
This study tests different treatment approaches for rhabdomyosarcoma (RMS) in children and adults, including newly diagnosed high-risk cases, people needing radiotherapy, and people whose RMS has returned. It’s designed to find safer dosing and more effective therapy while checking whether participants can proceed based on health and timing requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of rhabdomyosarcoma (RMS), not pleomorphic RMS
- You (or your parent/guardian) must be willing to sign informed consent
- Your trial group may require being in a certain risk level (high risk or very high risk) or relapsed disease
- You generally must not have had RMS treatment before (except surgery) for the frontline parts
- Your body must be able to handle treatment (blood counts, liver/kidney tests, and heart/overall health must meet limits)
- If you can become pregnant (or have a partner who can), you must use contraception for the study period and after
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way to treat rhabdomyosarcoma using a targeted drug (liposomal irinotecan) based on the tumor's genetic makeup and risk group. It aims to improve outcomes for children and young adults with intermediate or high-risk disease.
This trial compares two different chemotherapy schedules for children and young adults with intermediate-risk rhabdomyosarcoma (a type of muscle cancer). One group gets a higher dose of chemotherapy over a shorter period, while the other gets a lower dose plus maintenance therapy for a longer time. The goal is to see which approach works better.
This trial tests whether a cancer immunotherapy medicine (atezolizumab) given together with chemotherapy can shrink or control solid tumors that have come back or did not respond to prior treatment. It focuses on children and young adults, including a special subgroup for rhabdomyosarcoma.
This study tests different treatment plans for children with rhabdomyosarcoma based on their individual risk factors. It aims to find the best therapy for each child, potentially improving outcomes.
This early-phase trial tests a new immune cell therapy (CAR T cells) for children and young adults whose rhabdomyosarcoma has returned or not responded to standard treatments. The goal is to see if these specially engineered cells can find and attack the cancer.
This study looks at what makes people with rhabdomyosarcoma join or stay in clinical trials. It is an observational study, not a treatment test.
Hear when a new Rhabdomyosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.